0 CHECKOUT

Mild Cognitive Impairment - Pipeline Review, H2 2015

  • ID: 3429814
  • August 2015
  • 93 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Actinogen Limited
  • Boehringer Ingelheim GmbH
  • CereSpir Incorporated
  • D-Pharm Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • MORE

Mild Cognitive Impairment - Pipeline Review, H2 2015

Summary

The report ‘Mild cognitive impairment - Pipeline Review, H2 2015’, provides an overview of the Mild cognitive impairment’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mild cognitive impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild cognitive impairment and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Actinogen Limited
  • Boehringer Ingelheim GmbH
  • CereSpir Incorporated
  • D-Pharm Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Mild Cognitive Impairment Overview

Therapeutics Development

Pipeline Products for Mild Cognitive Impairment - Overview

Pipeline Products for Mild Cognitive Impairment - Comparative Analysis

Mild Cognitive Impairment - Therapeutics under Development by Companies

Mild Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes

Mild Cognitive Impairment - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Mild Cognitive Impairment - Products under Development by Companies

Mild Cognitive Impairment - Products under Investigation by Universities/Institutes

Mild Cognitive Impairment - Companies Involved in Therapeutics Development

Actinogen Limited

Avraham Pharmaceuticals Ltd.

Boehringer Ingelheim GmbH

CereSpir Incorporated

D-Pharm Ltd.

Eisai Co., Ltd.

Eli Lilly and Company

Octapharma AG

Sage Therapeutics

Sanofi

Suven Life Sciences Ltd.

Mild Cognitive Impairment - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

BAN-2401 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BCA-909 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CSP-1103 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DAOI-B - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DP-NDD - Drug Profile

Product Description

Mechanism of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

insulin (human) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ladostigil tartrate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

levetiracetam - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LY-3002813 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SAGE-547 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SAR-228810 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SUVN-501 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SUVN-502 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SUVN-507 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SUVN-512 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SUVN-976 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SUVND-4010 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tropisetron hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

UE-2343 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Mild Cognitive Impairment - Recent Pipeline Updates

Mild Cognitive Impairment - Dormant Projects

Mild Cognitive Impairment - Dormant Projects

Mild Cognitive Impairment - Discontinued Products

Mild Cognitive Impairment - Product Development Milestones

Featured News & Press Releases

Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment

Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI

Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON

May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment

Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m

Jul 27, 2009: Suven Presented Positive Phase-I Clinical Data Of SUVN-502 For Alzheimer’s Disease At ICAD 2009, Vienna, Austria.

Apr 09, 2009: Suven Completes Phase I Clinical Trials Multiple Ascending Dose Of SUVN-502 In Switzerland

Oct 13, 2008: Suven Announces That SUVN-502 Data Is Being Presented At 16th BioPartnering In London

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Mild Cognitive Impairment, H2 2015

Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Mild Cognitive Impairment - Pipeline by Actinogen Limited, H2 2015

Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H2 2015

Mild Cognitive Impairment - Pipeline by Boehringer Ingelheim GmbH, H2 2015

Mild Cognitive Impairment - Pipeline by CereSpir Incorporated, H2 2015

Mild Cognitive Impairment - Pipeline by D-Pharm Ltd., H2 2015

Mild Cognitive Impairment - Pipeline by Eisai Co., Ltd., H2 2015

Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H2 2015

Mild Cognitive Impairment - Pipeline by Octapharma AG, H2 2015

Mild Cognitive Impairment - Pipeline by Sage Therapeutics, H2 2015

Mild Cognitive Impairment - Pipeline by Sanofi, H2 2015

Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Mild Cognitive Impairment Therapeutics - Recent Pipeline Updates, H2 2015

Mild Cognitive Impairment - Dormant Projects, H2 2015

Mild Cognitive Impairment - Dormant Projects (Contd..1), H2 2015

Mild Cognitive Impairment - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Mild Cognitive Impairment, H2 2015

Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Routes of Administration, H2 2015

Number of Products by Stage and Routes of Administration, H2 2015

Number of Products by Molecule Types, H2 2015

Number of Products by Stage and Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Actinogen Limited
Avraham Pharmaceuticals Ltd.
Boehringer Ingelheim GmbH
CereSpir Incorporated
D-Pharm Ltd.
Eisai Co., Ltd.
Eli Lilly and Company
Octapharma AG
Sage Therapeutics
Sanofi
Suven Life Sciences Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Shire PLC.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Roche Diagnostics Ltd.
  • H. Lundbeck A/S
  • Electrical Geodesics, Inc.